NEW YORK, March 16 (GenomeWeb News) - Johnson & Johnson Pharmaceutical Research & Development will collaborate with Entelos to research multiple therapeutic areas for five more years, Entelos said today.
Under the agreement, Entelos engineers and scientists will use the PhysioLab platforms to "support specific projects ... on behalf of J&JPRD and its affiliates," the company said in a statement.
Financial details were not provided.
As GenomeWeb News reported last week, Entelos is unalarmed about the recent downsizing at J&JPRD. The two companies also recently expanded a hemotology research collaboration.
"We believe J&JPRD's continued commitment to apply the power of biosimulation to the drug discovery and development decisions will lead to safer and more effective medicines for patients," Entelos president and CEO James Karis said in a statement.